Apollomics, Inc. (APLM) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Apollomics, Inc. in 2026. The next earnings report is expected on September 24, 2026.
Next earnings date
24 Sep 2026
In 35 days
EPS estimate
—
Revenue estimate
—
Past earnings
No dividend history available.
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Apollomics, Inc. (APLM) is scheduled to report earnings on September 24, 2026.
Apollomics, Inc. (APLM) last reported earnings on March 30, 2026.
Apollomics, Inc. (APLM) is listed on Nasdaq.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.